iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
Yahoo Finance · Apr 8, 2026 · iBio, Inc. Common Stock (IBIO)
iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing “trust gap” between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market, according to Alex Taguchi, the company’s Director of Machine Learning. In a webinar presentation on
Not investment advice. Cached headline, not a full reprint.